Form 4: Sera Prognostics Director Sandra Lawrence Reports Significant Equity Grants

Sera Prognostics, Inc. Director Sandra AJ Lawrence has reported the acquisition of 15,596 restricted stock units and 25,000 stock options, vesting monthly over one year starting June 5, 2025.

Summary

• Sandra AJ Lawrence, a Director of Sera Prognostics, Inc. (SERA), reported new equity grants on June 5, 2025.
• The grants include 15,596 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs), acquired at a price of $0.
• Additionally, 25,000 stock options were granted with an exercise price of $1.6 per share, also acquired at a price of $0.
• Both the RSUs and stock options will vest over one year, with 1/12 of the original grant amount vesting in monthly installments following the vesting commencement date of June 5, 2025.
• Following these transactions, Sandra Lawrence beneficially owns 22,713 shares of Class A Common Stock and 25,000 stock options.
• The stock options were granted under Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan, and expire on June 5, 2035.

Sentiment

Score: 5

Explanation: Neutral. This is a factual disclosure of insider equity grants, which is a routine event and does not inherently convey positive or negative sentiment about the company's performance or outlook.

Positives

• The grants align the director's interests with those of shareholders by increasing her equity ownership in the company.
• The equity grants are part of a structured compensation policy, indicating standard corporate governance practices for non-employee directors.

Future Outlook

The grants of RSUs and stock options are structured to vest monthly over one year, commencing June 5, 2025, indicating a future increase in the director's direct beneficial ownership of company equity as vesting occurs.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, common across all industries for publicly traded companies. It reflects standard practices for aligning director incentives with long-term company performance.

Comparison to Industry Standards

• The structure of equity grants (RSUs and stock options) with a vesting schedule is a common compensation practice for non-employee directors across various industries, including biotechnology and diagnostics, similar to companies like Exact Sciences Corp. or Natera, Inc. which also utilize equity-based compensation to attract and retain board members.
• The vesting period of one year is a typical duration for such grants, aiming to retain directors and incentivize sustained performance.

Corporate Governance

Related Party Transactions

• The equity grants to Sandra AJ Lawrence, a director, constitute a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grants align the director's financial interests with shareholder value creation, as the value of the equity is tied to the company's stock performance.
• Employees: No direct impact on employees is indicated by this filing, though it reflects the company's overall compensation philosophy for key personnel.

Next Steps

• Monthly vesting of 1/12 of the granted RSUs and stock options will occur over the next year, starting June 5, 2025.
• The director will continue to provide services to the issuer for the RSUs to vest.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Sera Prognostics, SERA, Executive Compensation